Seres Therapeutics Inc. (NASDAQ:MCRB) traded down 2.9% during mid-day trading on Thursday . The stock traded as low as $10.55 and last traded at $10.64, with a volume of 396,560 shares trading hands. The stock had previously closed at $10.96.

Several equities research analysts have recently issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Sunday, May 29th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, July 19th. FBR & Co reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Monday, May 2nd. HC Wainwright assumed coverage on Seres Therapeutics in a research report on Friday, July 29th. They set a “buy” rating and a $50.00 target price for the company. Finally, Leerink Swann reiterated a “buy” rating and set a $12.00 price target on shares of Seres Therapeutics in a research note on Thursday, August 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $31.57.

The company’s market capitalization is $429.32 million. The company has a 50-day moving average of $20.42 and a 200 day moving average of $25.90.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.24. The firm earned $3 million during the quarter, compared to analysts’ expectations of $4.20 million. The firm’s revenue for the quarter was up NaN% on a year-over-year basis. During the same period last year, the business posted ($1.45) earnings per share. Analysts expect that Seres Therapeutics Inc. will post ($2.32) earnings per share for the current year.

In other news, CEO Roger Pomerantz sold 88,211 shares of the company’s stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $29.45, for a total value of $2,597,813.95. Following the completion of the transaction, the chief executive officer now owns 236,468 shares of the company’s stock, valued at $6,963,982.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider John G. Aunins sold 9,390 shares of the company’s stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $34.18, for a total value of $320,950.20. Following the completion of the transaction, the insider now directly owns 220,155 shares of the company’s stock, valued at approximately $7,524,897.90. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Seres Therapeutics stock. Jennison Associates LLC raised its position in Seres Therapeutics Inc. (NASDAQ:MCRB) by 1.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 398,959 shares of the company’s stock after buying an additional 7,259 shares during the period. Jennison Associates LLC owned approximately 1.02% of Seres Therapeutics worth $13,999,000 as of its most recent SEC filing.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.